← Leaderboards
Robert F Garry
Scripps Research Institute, The
$57,098,933
Attributed
$65,352,670
Total exposure
23
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$68,995,098 · 24
By mechanism
U19$23,507,364 · 6
R01$20,001,251 · 6
U01$19,323,237 · 2
UC1$3,860,593 · 1
R41$922,901 · 1
R21$885,765 · 2
Top collaborators
- Kristian Graugaard Andersen9 shared
- Pardis Christine Sabeti8 shared
Most similar at Scripps Research Institute, The
Same institution · by research overlap
- Kelly Keisen Lee$10,991,280
- Ian A Wilson$64,513,205
- Jiang Zhu$14,887,050
- Mansun Law$19,290,800
- Anne Dell$4,705,456
Others in their field
Top investigators on “Lassa Virus”
- Alessandro Sette · La Jolla Institute For Immunology$24,175,310
- Thomas William Geisbert · Boston University Medical Campus$20,808,527
- Sean M Amberg · Kineta, Inc.$18,993,187
- Pardis Christine Sabeti · Harvard University$18,428,342
- Juan C. De La Torre · Scripps Research Institute$17,235,707
- James Robinson · Tulane University Of Louisiana$16,224,928
Research focus
Lassa VirusAfricaVirusInfectionLassa FeverViral Hemorrhagic FeversAntibodiesNational Institute Of Allergy And Infectious DiseaseProgramsVaccinesVirus DiseasesRodentAfricanPublic HealthCollaborationsSierra LeoneArenavirusBaseNigeriaEvaluationClinical ResearchAchievementDisease OutbreaksNonhuman Primate
Grant awards (81)
Project 1$514,993
U19 · FY2025 · AI · contact PI
West African Emerging Infectious Disease Research Center (WA-EIDRC)$1,742,602
U01 · FY2024 · AI
West African Emerging Infectious Disease Research Center (WA-EIDRC)$819,744
U01 · FY2024 · AI
Project 1$405,445
U19 · FY2024 · AI · contact PI
West African Emerging Infectious Disease Research Center (WA-EIDRC)$1,741,300
U01 · FY2023 · AI
Preclinical Evaluation of Advanced Pan-Lassa Immunotherapeutic Cocktails$1,658,742
U19 · FY2023 · AI · contact PI
Project 1$884,500
U19 · FY2023 · AI · contact PI
West African Emerging Infectious Disease Research Center (WA-EIDRC)$801,785
U01 · FY2023 · AI
West African Emerging Infectious Disease Research Center (WA-EIDRC)$236,024
U01 · FY2023 · AI
West African Emerging Infectious Disease Research Center (WA-EIDRC)$1,848,854
U01 · FY2022 · AI
West African Emerging Infectious Disease Research Center (WA-EIDRC)$1,749,860
U01 · FY2022 · AI
Preclinical Evaluation of Advanced Pan-Lassa Immunotherapeutic Cocktails$1,658,676
U19 · FY2022 · AI · contact PI
Systems-level identification of host determinants of patient outcomes in Lassa fever and Ebola$425,000
U19 · FY2022 · AI · contact PI
Systems-level identification of host determinants of patient outcomes in Lassa fever and Ebola$74,999
U19 · FY2022 · AI · contact PI
Preclinical Evaluation of Advanced Pan-Lassa Immunotherapeutic Cocktails$1,831,899
U19 · FY2021 · AI · contact PI
West African Emerging Infectious Disease Research Center (WA-EIDRC)$1,757,660
U01 · FY2021 · AI
Structure-based design of novel Lassa virus glycoproteins for vaccine development$1,172,924
R01 · FY2021 · AI · contact PI
Preclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktail$1,124,215
R01 · FY2021 · AI · contact PI
Systems-level identification of host determinants of patient outcomes in Lassa fever and Ebola$439,968
U19 · FY2021 · AI · contact PI
Structure-based design of novel Lassa virus glycoproteins for vaccine development$143,668
R01 · FY2021 · AI · contact PI
Systems-level identification of host determinants of patient outcomes in Lassa fever and Ebola$105,388
U19 · FY2021 · AI · contact PI
Structure-based design of novel Lassa virus glycoproteins for vaccine development$36,152
R01 · FY2021 · AI · contact PI
Preclinical Evaluation of Advanced Pan-Lassa Immunotherapeutic Cocktails$2,258,151
U19 · FY2020 · AI · contact PI
West African Emerging Infectious Disease Research Center (WA-EIDRC)$1,883,223
U01 · FY2020 · AI
Structure-based design of novel Lassa virus glycoproteins for vaccine development$1,177,630
R01 · FY2020 · AI · contact PI
Preclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktail$1,108,530
R01 · FY2020 · AI · contact PI
Systems-level identification of host determinants of patient outcomes in Lassa fever and Ebola$601,080
U19 · FY2020 · AI · contact PI
Preclinical Evaluation of Advanced Pan-Lassa Immunotherapeutic Cocktails$1,906,843
U19 · FY2019 · AI · contact PI
Structure-based design of novel Lassa virus glycoproteins for vaccine development$1,198,010
R01 · FY2019 · AI · contact PI
Preclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktail$1,111,574
R01 · FY2019 · AI · contact PI
Systems-level identification of host determinants of patient outcomes in Lassa fever and Ebola$775,214
U19 · FY2019 · AI · contact PI
International Collaboration in Infectious Disease Research on Lassa fever$668,295
U19 · FY2019 · AI · contact PI
Lassa ICIDR - Administrative Core$70,231
U19 · FY2019 · AI · contact PI
Structure-based design of novel Lassa virus glycoproteins for vaccine development$1,208,740
R01 · FY2018 · AI · contact PI
Immunotherapeutics Against Arenaviruses$1,149,274
U19 · FY2018 · AI · contact PI
Preclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktail$1,116,401
R01 · FY2018 · AI · contact PI
International Collaboration in Infectious Disease Research on Lassa fever$857,925
U19 · FY2018 · AI · contact PI
Systems-level identification of host determinants of patient outcomes in Lassa fever and Ebola$655,361
U19 · FY2018 · AI · contact PI
Lassa ICIDR - Administrative Core$252,509
U19 · FY2018 · AI · contact PI
Structure-based design of novel Lassa virus glycoproteins for vaccine development$1,562,780
R01 · FY2017 · AI · contact PI
Preclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktail$1,268,148
R01 · FY2017 · AI · contact PI
Immunotherapeutics Against Arenaviruses$1,205,553
U19 · FY2017 · AI · contact PI
Antibody immunotherapeutics for biodefense against Lassa virus$1,148,492
R01 · FY2017 · AI · contact PI
International Collaboration in Infectious Disease Research on Lassa fever$675,365
U19 · FY2017 · AI · contact PI
Lassa ICIDR - Administrative Core$67,315
U19 · FY2017 · AI · contact PI
Antibody immunotherapeutics for biodefense against Lassa virus$1,238,702
R01 · FY2016 · AI · contact PI
Immunotherapeutics Against Arenaviruses$913,967
U19 · FY2016 · AI · contact PI
International Collaboration in Infectious Disease Research on Lassa fever$770,315
U19 · FY2016 · AI · contact PI
Lassa ICIDR - Administrative Core$153,348
U19 · FY2016 · AI · contact PI
Antibody immunotherapeutics for biodefense against Lassa virus$1,010,001
R01 · FY2015 · AI · contact PI
Immunotherapeutics Against Arenaviruses$774,498
U19 · FY2015 · AI · contact PI
International Collaboration in Infectious Disease Research on Lassa fever$670,528
U19 · FY2015 · AI · contact PI
Lassa ICIDR - Administrative Core$66,912
U19 · FY2015 · AI · contact PI
Antibody immunotherapeutics for biodefense against Lassa virus$1,105,698
R01 · FY2014 · AI · contact PI
Immunotherapeutics Against Arenaviruses$1,015,070
U19 · FY2014 · AI · contact PI
Antibody immunotherapeutics for biodefense against Lassa virus$1,337,737
R01 · FY2013 · AI · contact PI
Preclinical development of recombinant antigen diagnostics for Lassa fever$1,237,152
U01 · FY2013 · AI · contact PI
Opening a New Lassa Fever Ward in Kenema Sierra Leone$8,000
R13 · FY2013 · AI · contact PI
Preclinical development of recombinant antigen diagnostics for Lassa fever$1,316,120
U01 · FY2012 · AI · contact PI
Preclinical development of recombinant antigen diagnostics for Lassa fever$1,335,377
U01 · FY2011 · AI · contact PI
Preclinical development of recombinant antigen diagnostics for Lassa fever$1,353,910
U01 · FY2010 · AI · contact PI
Preclinical development of recombinant antigen diagnostics for Lassa fever$1,499,626
U01 · FY2009 · AI · contact PI
COINCIDENT AIDS/RELAPSING MALARIA$63,253
P51 · FY2008 · RR · contact PI
Peptide drugs against influenza virus$461,944
R41 · FY2007 · AI · contact PI
COINCIDENT AIDS/RELAPSING MALARIA$71,638
P51 · FY2007 · RR · contact PI
Peptide drugs against influenza virus$460,957
R41 · FY2006 · AI · contact PI
Peptide inhibitors of dengue virus infectivity$303,935
R56 · FY2006 · AI · contact PI
HIV-1 Tat modulation of HCV replication and pathogenesis$217,515
R21 · FY2006 · DK · contact PI
Recombinant antigen assays for Lassa and other arenaviru$3,860,593
UC1 · FY2005 · AI
Rapid screen for Ebola virus membrane interactions/drugs$259,875
R01 · FY2005 · AI
HIV-1 Tat modulation of HCV replication and pathogenesis$222,750
R21 · FY2005 · DK
Primate pilot study: coincident AIDS/relapsing malaria$375,655
R01 · FY2004 · RR
Rapid screen for Ebola virus membrane interactions/drugs$259,875
R01 · FY2004 · AI
Rapid screen for HIV TM membrane interactions/drugs$222,750
R21 · FY2004 · AI
COINCIDENT AIDS/RELAPSING MALARIA$47,161
P51 · FY2004 · RR
Primate pilot study: coincident AIDS/relapsing malaria$540,471
R01 · FY2003 · RR
Rapid screen for Ebola virus membrane interactions/drugs$259,875
R01 · FY2003 · AI
Rapid screen for HIV TM membrane interactions/drugs$222,750
R21 · FY2003 · AI
MEASUREMENT OF VIROLOGIC AND IMMUNOLOGIC PARAMETERS IN HIV$0
M01 · FY2001 · RR
ALTERATIONS OF ION TRANSPORT BY HIV$236,098
R01 · FY2000 · AI
MEASUREMENT OF VIROLOGIC AND IMMUNOLOGIC PARAMETERS IN HIV$0
M01 · FY2000 · RR